




## Bovine Type II Collagen

Cat. No.	Format	Size
1220-02	Purified Protein - Lyophilized	0.25 mg
1220-02S	Purified Protein - Solution	0.5 mg



ELISA plate was coated with serially diluted Bovine Type II Collagen (SB Cat. No. 1220-02). Purified collagen was detected with Goat Anti-Type I Collagen-BIOT (SB Cat. No. 1310-08), Goat Anti-Type II Collagen-BIOT (SB Cat. No. 1320-08), Goat Anti-Type III Collagen-BIOT (SB Cat. No. 1330-08), Goat Anti-Type IV Collagen-BIOT (SB Cat. No. 1340-08), Goat Anti-Type V Collagen-BIOT (SB Cat. No. 1350-08), and Goat Anti-Type VI Collagen-BIOT (SB Cat. No. 1360-08) followed by Streptavidin-HRP (SB Cat. No. 7100-05).

### Overview

<b>Source</b>	Cartilage
<b>Purification</b>	Controlled and limited pepsin digestion followed by selective salt precipitation
<b>Purity</b>	> 90% by SDS-PAGE
<b>Alternate Name(s)</b>	COL2A1

### Description

Collagen is the main structural protein in the extracellular space and is the most abundant protein in the ECM. Collagens are divided into two classes - fibril (types I, II, III, V) and non-fibril (types IV, VI). Type II collagen is the main component of cartilage and mutations are associated several types of chondrodysplasia. Type II collagen is formed by homotrimers of  $\alpha 1(\text{II})$  chains.

### Applications

ELISA – Quality tested <sup>1,10</sup>  
 SDS-PAGE – Quality tested <sup>2</sup>  
 WB – Reported in literature <sup>3,4</sup>  
*In vivo* Assays – Reported in literature <sup>5-8</sup>  
 Coating Material for –  
     ECM Interaction Studies – Reported in literature <sup>9</sup>  
     Migration Studies – Reported in literature <sup>10</sup>

### Handling and Storage

- The purified protein is supplied as a solution of 0.5 mg collagen in 1.0 mL of 500 mM acetic acid or 0.25 mg collagen lyophilized from 500 mM acetic acid. Store at 2-8°C.
- Reconstitute lyophilized protein in 500 mM acetic acid.
- Reagents are stable for the period shown on the label if stored as directed.

### Warning

Reagents contain acetic acid. Please refer to product specific SDS.

**For Research Use Only. Not for Diagnostic or Therapeutic Use.**

## References

---

1. Frenz DA, Liu W, Williams JD, Hatcher V, Galinovic-Schwartz V, Flanders KC, et al. Induction of chondrogenesis: requirement for synergistic interaction of basic fibroblast growth factor and transforming growth factor-beta. *Development*. 1994;120:415-24. (ELISA, Standard Curve)
2. Geng Y, McQuillan D, Roughley PJ. SLRP interaction can protect collagen fibrils from cleavage by collagenases. *Matrix Biol*. 2006;25:484-91. (SDS-PAGE)
3. Patti JM, Jonsson H, Guss B, Switalski LM, Wiberg K, Lindberg M, et al. Molecular characterization and expression of a gene encoding a *Staphylococcus aureus* collagen adhesin. *J Biol Chem*. 1992;267:4766-72. (WB)
4. Lee ER, Lamplugh L, Kluczyk B, Leblond CP, Mort JS. Neopeptides reveal the features of type II collagen cleavage and the identity of a collagenase involved in the transformation of the epiphyses anlagen in development. *Dev Dyn*. 2009;238:1547-63. (WB)
5. Little RG II, Gazzano-Santoro H, Parent JB, inventors; Xoma Corporation, assignee. Therapeutic uses of bactericidal/permeability increasing protein products. United States patent US 1994/5348942A. 1994 Sep 20. (*In vivo* Assays)
6. Burlingham WJ, Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. *J Clin Invest*. 2007;117:3498-506. (*In vivo* Assays)
7. Iwai K, Ishii M, Ohshima S, Miyatake K, Saeki Y. Abundant expression of tetraspanin CD9 in activated osteoclasts in ovariectomy-induced osteoporosis and in bone erosions of collagen-induced arthritis. *Rheumatol Int*. 2008;28:225-31. (*In vivo* Assays)
8. Dart ML, Jankowska-Gan E, Huang G, Roenneburg DA, Keller MR, Torrealba JR, et al. Interleukin-17-dependent autoimmunity to collagen type V in atherosclerosis. *Circ Res*. 2010;107:1106-16. (*In vivo* Assays)
9. Hocking AM, Strugnell RA, Ramamurthy P, McQuillan DJ. Eukaryotic expression of recombinant biglycan. Post-translational processing and the importance of secondary structure for biological activity. *J Biol Chem*. 1996;271:19571-7. (Coating, ECM Interaction Studies)
10. Hidaka C, Cheng C, Alexandre D, Bhargava M, Torzilli PA. Maturation differences in superficial and deep zone articular chondrocytes. *Cell Tissue Res*. 2006;323:127-35. (ELISA, Standard Curve, Coating, Migration Studies)